SCHEMBL25357358

SCHEMBL25357358

CC(C)n1nc(I)c(=O)c2ccc(Br)cc21

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 4/20 0.48
▸ PDGFRA P16234 1/20 0.38
▸ CDK5 Q00535 1/20 0.38
▸ TYRO3 Q06418 1/20 0.38
▸ CHEK1 O14757 1/20 0.33
▸ MAPK8 P45983 1/20 0.33
▸ HAVCR2 Q8TDQ0 1/20 0.32
▸ FABP4 P15090 1/20 0.32
▸ RET P07949 1/20 0.31
▸ DDB1 Q16531 1/20 0.31
▸ CRBN Q96SW2 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ HSP90AA1 P07900 1/20 0.30
▸ TLR9 Q9NR96 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25036653 0.91 NLRP3 (0.44) NLRP3PDGFRACDK5TYRO3CHEK1
SCHEMBL25360566 0.82 NLRP3 (0.48) NLRP3PDGFRACDK5TYRO3CHEK1
SCHEMBL13886067 0.78 ALDH1A1 (0.41) ALDH1A1KMT2A
SCHEMBL25356861 0.77 NLRP3 (0.57) NLRP3PDGFRACDK5TYRO3CHEK1
SCHEMBL25357137 0.77 NLRP3 (0.44) NLRP3PDGFRACDK5TYRO3CHEK1
SCHEMBL16596067 0.76 GRM4 (0.43) NLRP3PDGFRACDK5TYRO3MAPK8
SCHEMBL29492185 0.76 NLRP3 (0.64) NLRP3PDGFRACDK5TYRO3MEN1
SCHEMBL25356370 0.76 NLRP3 (0.53) NLRP3PDGFRACDK5TYRO3MAPK8
SCHEMBL13322761 0.75 PDGFRA (0.55) NLRP3PDGFRACDK5TYRO3CHEK1
SCHEMBL498685 0.73 NLRP3 (0.46) NLRP3PDGFRACDK5TYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217346-B1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2025-07-02 — — EP disclosed
US-20230391756-A1 NEW COMPOUND JANSSEN PHARMACEUTICA NV (BE) 2023-12-07 — — US disclosed
EP-4217346-A1 NEW COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
CN-116323585-A New compounds 詹森药业有限公司 2023-06-23 — — CN disclosed
WO-2022063876-A1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391756-A1 NEW COMPOUND NLRP3, NLRP1, IL1R1 NLRP3 1/4885PDGFRA 4323/4885CDK5 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback